Drug discovery summit on anti-inflammation and immune diseases. Immune-mediated diseases--second international meeting. 8-9 March 2004, Baltimore, MD, USA.
Braddock
Martin
M
AstraZeneca R&D, Discovery Biosciences Division, Loughborough, Leicestershire, LE11 5RH, UK. martin.braddock@astrazeneca.com
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000138:chemical synthesis* / Q000494:pharmacology; D000906:Antibodies / Q000627:therapeutic use; D065095:Calcineurin Inhibitors; D004791:Enzyme Inhibitors; D006801:Humans; D007154:Immune System Diseases / Q000188:drug therapy* / Q000473:pathology; D007249:Inflammation / Q000188:drug therapy* / Q000473:pathology; D008562:Membrane Glycoproteins / Q000187:drug effects; D000587:Oxidoreductases Acting on CH-NH Group Donors / Q000037:antagonists & inhibitors; D011956:Receptors, Cell Surface / Q000187:drug effects; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D051193:Toll-Like Receptors
D000893:Anti-Inflammatory Agents; D000906:Antibodies; D065095:Calcineurin Inhibitors; D004791:Enzyme Inhibitors; D008562:Membrane Glycoproteins; D011956:Receptors, Cell Surface; D051193:Toll-Like Receptors; D000587:Oxidoreductases Acting on CH-NH Group Donors